FTC continues campaign against reverse payments
09 February 2009
Eileen McDermott, New York
In its latest bid to curb reverse payments between innovator pharmaceutical companies and generics, the US Federal Trade Commission has filed a complaint against Solvay Pharmaceuticals and three generic drug makers
The FTC complaint alleges that Watson Pharmaceuticals, Par Pharmaceuticals and Paddock Laboratories agreed to abandon their Abbreviated New Drug Application (ANDA) with the...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial